Tariffs Threaten Pharmaceutical Access and Innovation

Recently, the White House announced its plans to impose a “major tariff” on imported pharmaceuticals. These tariffs would affect not only finished drug products, but also Active Pharmaceutical Ingredients (APIs) and other components that are used in domestic pharmaceutical manufacturing. There are implications for the global supply chain of medicines, insurance costs for pharmaceuticals, and patients’ access to medicines.

Andrew Spiegel, CEO of the Global Colon Cancer Association and board chair of the World Patients Alliance, penned an op-ed in Real ClearHealth on the tariffs and how they will hurt patients and hinder development of new cancer treatments.

Read the op-ed, “Don’t Let Patients Become Collateral Damage in a Trade War”.

GCCA is committed to policies that put patients first and protect continued access to life-saving innovation.

‍